ImmunityBio awards $805K bonuses, 3.2M options, RSUs; sets 2024 exec pay

ImmunityBio, Inc.

2023 bonuses: Soon-Shiong $232,875, Adcock $298,500, Sachs $273,980; payable by March 15, 2024.
Option grants: Soon-Shiong 1.19M NSOs, Adcock 1.59M ISOs, Sachs 424K ISOs at $5.24 strike.
RSU grants: Soon-Shiong 342,987, Adcock 457,317, Sachs 121,951; vest ratably over 3 years.
2024 salary/target bonus: Soon-Shiong $621K/75%, Adcock $796K/75%, Sachs $575K/50%.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ImmunityBio, Inc.: Board approved a new Code of Business Conduct and Ethics, replacing the prior Code of Global Business Conduct and Ethics, with updated and enhanced provisions including policies on fair dealing and healthcare law compliance (effective 2024-02-22).

Change: code of ethics
Effective: 2024-02-22

Exact text from the filing

On February 22, 2024, the Board of Directors (the “Board”) of the Company approved a Code of Business Conduct and Ethics to replace the Company’s prior Code of Global Business Conduct and Ethics (each acting as the Company’s “Code of Ethics”).

View on SEC.gov

Browse all governance changes →

ImmunityBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-044886

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.